Oral proteolytic enzymes such as serratiopeptidase, chymotrypsins, trypsin, and bromelain, etc., are aggressively marketed in India for their anti-inflammatory action and are prescribed in a variety of conditions like facial edema, trauma, surgery, parotitis, and carpal tunnel syndrome. But they are not approved by FDA. Significance of Proteolytic enzymes assessed through the prescription pattern. The study was conducted to assess the prescription pattern of Proteolytic enzymes at a tertiary care teaching hospital. A Hospital-based Prospective Observational Study was conducted for 5months from November 2021 to March 2022 to analyze the prescription pattern of proteolytic enzymes in both In-patients and Out-patients of various departments as Orthopaedics, ENT, Surgery, General medicine, and Dental. The data were entered in MS Excel 2010 and the results were expressed in frequency and percentage. During the study period, a total of 79 patients were enrolled among which males were found to be more who were prescribed with Proteolytic enzymes. It was found that Proteolytic enzymes were mostly prescribed in Orthopaedic department (58.2%). FDC of Proteolytic enzyme which contains Trypsin(48mg)+Bromelain(90mg)+Rutoside(100mg) sold under the brand name Enzomac (50.63%) was most commonly prescribed. Among the study population, the commonly prescribed combination drugs were NSAIDs (74.7%), Muscle relaxants (2.5%), narcotic analgesics (10.1%), and Non- Opioid analgesics (6.3%). From our results, we recommend that future studies are necessary to be conducted to prove the efficacy and tolerability of the Proteolytic enzyme as a promising therapeutic agent.